Detection of recombinant epoetin and darbepoetin alpha after subcutaneous administration in the horse.

This study presents a new method for detecting the misuse of a specific performance-enhancing drug (recombinant human erythropoietin) in racehorses. It involves two stages: an initial screening of the horse’s blood, followed by a more detailed analysis of its urine.

Research Background

• The paper discusses the development of a new method to detect the abuse of recombinant human erythropoietin (rHuEPO), a type of performance-enhancing drug in racehorses.
• rHuEPO and its hyper-glycosylated form (darbepoetin alpha) are drugs used to stimulate the production of red blood cells, which can erroneously enhance a horse’s athletic performance.

Proposed Detection Method

• The proposed method is a two-step process involving initial screening and then confirmation.
• The first stage is the screening of horse’s plasma or serum using an enzyme-linked immunosorbent assay (ELISA) that is specific for human EPO. ELISA is a common laboratory test that uses antibodies and color change to identify a substance; in this case, it’s used to detect the presence of synthetic EPO.
• If the initial screening test is positive, it is then confirmed through a more detailed analysis of the horse’s urine. The method characterizes the urinary EPO isoelectric profile, which involves studying the charge properties of EPO molecules present in the urine.

Testing and Application

• The researchers tested this method on horses that were administered with the two forms of the drug: rHuEPO (epoetin alpha) and the hyper-glycosylated form (darbepoetin alpha).
• The result of the research is crucial for setting up better anti-doping control measures in horse racing and could potentially be used as a standard procedure in the industry for detecting the abuse of these substances.